<DOC>
	<DOCNO>NCT02815488</DOCNO>
	<brief_summary>CHF6297 potent selective inhibitor human MAP kinase p38 develop anti-inflammatory agent treatment inflammatory airways disease . The purpose study evaluate safety , tolerability , pharmacokinetics pharmacodynamics single repeat dos CHF6297 dry powder formulation healthy subject COPD patient . This study first administration human . The study comprise four part : Part 1 consist two cohort healthy male subject assess safety , tolerability pharmacokinetics Single Ascending Dose ( SAD ) CHF6297 . Part 2 consist four cohort healthy male subject assess safety , tolerability pharmacokinetics Multiple Ascending Dose ( MAD ) CHF6297 . Part 3 consist one cohort COPD patient assess safety , tolerability , pharmacokinetics pharmacodynamics repeat dose CHF6297 Part 4 consist one cohort healthy subject assess anti-inflammatory effect repeat dose CHF6297 LPS challenge .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics Pharmacodynamics Single Repeat Doses CHF6297 Healthy Subjects Patients With COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Inclusion criterion : Part 1 , Part 2 , Part 4 ( Healthy subject ) : Male subject age 1855 year ; Non smoker Lung function 80 % predict normal value Healthy subject base medical evaluation include medical history , physical examination , laboratory test cardiac test ability produce adequate induce sputum sample ( study part 4 ) Part 3 ( COPD patient ) : Males female age 4075 year Current past smoker stable patient postbronchodilator FEV1 40 80 % predict normal value FEV1/FVC ratio &lt; 0.7 Ability produce spontaneous adequate induce sputum sample Parts 1,2 , 4 ( Healthy subject ) : Any clinically relevant abnormality and/or uncontrolled disease Abnormal laboratory value Recent respiratory tract infection Hypersensitivity drug excipients Positive serology result Positive cotinine , alcohol , drug abuse test Part 3 ( COPD patient ) : Females childbearing potential History asthma Unstable concomitant diseases Abnormal relevant Holter ECG parameter Recent acute exacerbation COPD respiratory tract infection Hypersensitivity drug excipients Positive serology result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>